Combination chemotherapy with pazopanib and ICE in children and adolescents with relapsed/refractory solid tumors
- Conditions
- Neoplasms
- Registration Number
- KCT0003260
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Terminated
- Sex
- All
- Target Recruitment
- 46
•Patients with refractory/relapsed solid tumor (Stable or progressive disease after 1st-line treatment or relapse)
•Patients previously enrolled to Genomic diagnosis of pediatric tumors by NGS (IRB No. SMC 2015-11-053)
•Patients who had high-dose chemotherapy and autologous stem cell transplantation previously
•Patients with organ dysfunction as follows (creatinine elevation = 1.5 x upper limit of normal (ULN), ejection fraction <40%, significant arrhythmia or conduction disturbance)
•Patients who are not eligible to have scheduled treatment due to the other significant impaired organ function
•Patients with active bleeding
•Patients who are taking strong CYP3A4 inhibitors, QTc-prolonging drugs, antithrombotic agents, or anti-platelet agents
•Pregnant or nursing women
•Patients who can not swallow the pill
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MTD of Pazopanib in combination chemotherapy;Response rate
- Secondary Outcome Measures
Name Time Method Progression free survival